MU OPIOID RECEPTOR mRNA LEVELS FOLLOWING CHRONIC ADMINISTRATION OF OPIOID LIGANDS

Analgesia ◽  
1995 ◽  
Vol 1 (4) ◽  
pp. 805-808 ◽  
Author(s):  
Ellen M. Unterwald ◽  
Joshua M. Rubenfeld ◽  
Jason Kreuter ◽  
Mary Jeanne Kreek
2002 ◽  
Vol 58 (3) ◽  
pp. 285-288 ◽  
Author(s):  
Eugene D Festa ◽  
Christine Cecala ◽  
Vanya Quinones-Jenab ◽  
Shirzad Jenab

1995 ◽  
Vol 33 (2) ◽  
pp. 351-355 ◽  
Author(s):  
Ellen M. Unterwald ◽  
Joshua M. Rubenfeld ◽  
Yasuo Imai ◽  
Jia-Bei Wang ◽  
George R. Uhl ◽  
...  

1999 ◽  
Vol 48 (1) ◽  
pp. 109-112 ◽  
Author(s):  
Vadim Yuferov ◽  
Yan Zhou ◽  
Rudolph Spangler ◽  
Christopher E Maggos ◽  
Ann Ho ◽  
...  

1997 ◽  
Vol 87 (5) ◽  
pp. 1127-1138 ◽  
Author(s):  
Elizabeth K. Gies ◽  
Dawn M. Peters ◽  
Carol R. Gelb ◽  
Kathleen M. Knag ◽  
Robert A. Peterfreund

Background The mu opioid receptor (MuOR) is a member of the superfamily of G protein-coupled receptors that mediates the analgesic actions of endogenous opioid peptides and the narcotic alkaloid derivatives of morphine. Activation and translocation of protein kinase C (PKC) by N-methyl-D-aspartate receptor stimulation correlates with resistance to opioid drugs in experimental states of neuropathic pain, but the cellular mechanisms of resistance have not been identified. One possibility is that PKC activation regulates MuOR mRNA expression and thus the ability to generate functional receptors. Using a human neuroblastoma cell line, the authors tested the hypothesis that phorbol ester activation of PKC regulates MuOR mRNA levels. Methods SH-SY5Y cells were maintained in a continuous monolayer culture and treated with phorbol esters or other agents before extraction of total cellular RNA. Slot-blot hybridization was used to measure the level of MuOR mRNA using 32P-labeled MuOR cDNA probes under high-stringency conditions. Autoradiograms were analyzed by scanning and densitometry. Results MuOR mRNA levels decreased in a dose- and time-dependent manner after tetradecanoyl phorbol acetate (TPA) was administered to activate PKC. The nadir, a level of approximately 50% of control, was at 2-8 h, followed by gradual recovery. The actions of TPA were blocked by pretreatment with the selective PKC inhibitor bisindolylmaleimide, but not by inhibition of protein synthesis with cycloheximide or anisomycin. The combination of TPA treatment and transcription inhibition with actinomycin D was associated with a transient increase in MuOR mRNA. Conclusions Mu opioid receptor mRNA levels are regulated by activation of PKC in a neuronal model. Protein kinase C effects which decrease MuOR mRNA levels appear largely independent of new protein synthesis, and cytotoxicity does not account for the findings. Plasticity of MuOR gene expression may contribute to variations in clinical responses to opioid analgesics in clinical states such as neuropathic pain.


1994 ◽  
Vol 54 (1) ◽  
pp. 307-308 ◽  
Author(s):  
E.M. Unterwald ◽  
J.M. Rubenfeld ◽  
R. Spangler ◽  
Y. Imai ◽  
J.B. Wang ◽  
...  

2014 ◽  
Vol 112 (1) ◽  
pp. 279-284 ◽  
Author(s):  
Jin Xu ◽  
Andrew J. Faskowitz ◽  
Grace C. Rossi ◽  
Mingming Xu ◽  
Zhigang Lu ◽  
...  

Chronic morphine administration is associated with the development of tolerance, both clinically and in animal models. Many assume that tolerance is a continually progressive response to chronic opioid dosing. However, clinicians have long appreciated the ability to manage cancer pain in patients for months on stable opioid doses, implying that extended dosing may eventually result in a steady state in which the degree of tolerance remains constant despite the continued administration of a fixed morphine dose. Preclinical animal studies have used short-term paradigms, typically a week or less, whereas the clinical experience is based upon months of treatment. Chronic administration of different fixed morphine doses produced a progressive increase in the ED50 that peaked at 3 wk in mice, consistent with prior results at shorter times. Continued morphine dosing beyond 3 wk revealed stabilization of the level of tolerance for up to 6 wk with no further increase in the ED50. The degree of tolerance at all time points was dependent upon the dose of morphine. The mRNA levels for the various mu opioid receptor splice variants were assessed to determine whether stabilization of morphine tolerance was associated with changes in their levels. After 6 wk of treatment, mRNA levels of the variants increased as much as 300-fold for selected variants in specific brain regions. These findings reconcile preclinical and clinical observations regarding the development of morphine tolerance.


Sign in / Sign up

Export Citation Format

Share Document